Viking Therapeutics, Inc. (VKTX)
| Market Cap | 4.07B +29.0% |
| Revenue (ttm) | n/a |
| Net Income | -359.64M |
| EPS | -3.19 |
| Shares Out | 115.55M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,283,527 |
| Open | 35.90 |
| Previous Close | 35.76 |
| Day's Range | 34.57 - 36.21 |
| 52-Week Range | 18.92 - 43.15 |
| Beta | 0.79 |
| Analysts | Strong Buy |
| Price Target | 88.00 (+149.72%) |
| Earnings Date | Apr 22, 2026 |
About VKTX
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II c... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for VKTX stock is "Strong Buy." The 12-month stock price target is $88.0, which is an increase of 149.72% from the latest price.
News
Viking Therapeutics, Inc. (VKTX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Viking Therapeutics, Inc. (VKTX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Viking Therapeutics to Participate at Upcoming Investor Conferences
SAN DIEGO, March 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and...
Viking Therapeutics Stock Gains Amid Obesity Drug Buzz
Novo Nordisk's stock hit a 52-week low after its REDEFINE 4 trial failed to demonstrate non-inferiority in weight loss compared to Eli Lilly's tirzepatide, marketed under the Zepbound and Mounjaro bra...
Viking Therapeutics: Full-Speed Ahead
Viking Therapeutics is aggressively advancing its GLP-1 pipeline, with two pivotal Phase 3 trials now underway or imminent. VKTX's Phase 2 oral data showed up to 14.7% weight loss in 13 weeks, positio...
Viking Therapeutics: Buyers Are Quietly Accumulating On Its Obesity Drugs Launch Potential
Viking Therapeutics is still kept as a speculative buy, with selling pressure subsiding and constructive consolidation signaling renewed investor interest. VKTX's dual-track pipeline and manufacturing...
Viking Therapeutics, Inc. (VKTX) Q4 2025 Earnings Call Transcript
Viking Therapeutics, Inc. (VKTX) Q4 2025 Earnings Call Transcript
Viking Therapeutics plans to advance oral obesity drug to late-stage trial
Viking Therapeutics said on Wednesday that it plans to test its experimental oral obesity drug in a late-stage study later this year.
Viking Therapeutics Stock Climbs After Q4 Report: Details
Viking Therapeutics, Inc. (NASDAQ:VKTX) shares climbed in Wednesday's extended trading after the company released its fourth-quarter earnings report.
Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today Oral VK2735 to Advance into Phase 3 for Obesity in 3Q26 Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Ongoing; VANQUISH-1 Enrollment Compl...
The Commoditization Of GLP-1s: Why Viking's Maintenance Hedge Is Falling Short
Viking Therapeutics, Inc. faces significant challenges with VK2735, lacking differentiation from established obesity treatments like ZEPBOUND and WEGOVY. Phase 2 data highlight tolerability issues at ...
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026
Conference Call Scheduled for Wednesday, February 11 at 4:30 p.m. Eastern Time SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmac...
Obesity stocks slump on Novo's underwhelming 2026 sales forecast
Shares of obesity drugmakers and developers slid on Tuesday after Novo Nordisk forecast a sharper-than-expected sales decline for 2026, underscoring intensifying competition in the blockbuster weight-...
Viking Therapeutics, Inc. (VKTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Viking Therapeutics, Inc. (VKTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Appetite for weight-loss deals broader than visible, Viking CEO says
Weight-loss drug developer Viking Therapeutics CEO said on Monday that strategic interest in weight-loss drug deals is broader than it appears, as drugmakers seek to tap into the potential $150 billio...
Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity
Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed VK2735 Currently Being Evaluated in VANQUISH Phase 3 Registrational Program ...
Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity
Study is Evaluating Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens Designed to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735 SAN DIEGO, Jan. 8, 2026 /PRNews...
Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer
Experienced Industry Leader with More than Two Decades of Global Commercialization and Marketing Expertise SAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a ...
Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and ...
Novo Nordisk's weight-loss pill is available. Here's why Lilly's and Viking's stocks are down.
Novo Nordisk's wildly successful obesity medicine is now available as a pill, making it the first GLP-1 pill for weight loss in the U.S.
Viking Therapeutics: The Obesity Drugs Gold Rush Is Far From Over
Viking Therapeutics remains a compelling obesity drugs contender, despite being in the pre-commercial phase. VKTX's dual-track pipeline (injectable and oral) and robust $700M liquidity position it wel...
Viking Therapeutics: A Wide-Open Oral GLP-1 Market
Viking Therapeutics is positioned favorably in the oral GLP-1 obesity drug race, with strong Phase 2 results for VK2735. VKTX's oral candidate achieved 12.2% weight loss at the highest dose in 13 week...
Viking Therapeutics' Swing Trade Potential Emerges - Competition/Dilution Risks Remain
VKTX remains a Buy for its cheap FY2030 EV/Sales valuations of 2.28x, the strong clinical trial results exceeding legacy players, and the potential GLP-1 monetization upon US FDA approval. The managem...
Viking Therapeutics: Prepping For A Critical 2026
Viking Therapeutics is positioned for a pivotal 2026, advancing both injectable and oral VK2735 in obesity, with pipeline depth from an emerging amylin agonist program. VKTX's oral VK2735 has demonstr...
Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference
SAN DIEGO , Nov. 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic an...
3 Weight-Loss Drug Stocks To Consider For 2026
The global weight loss drug market, perhaps ironically, is growing like gangbusters these days. Globally, it's set to expand from $15 billion in 2024 to $150 billion by 2035, according to Morgan Stanl...